M. Mackean

发表

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

R. L. Hollis, A. Biankin, A. Matakidou, 2020, Clinical Cancer Research.

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

M. Gore, G. Hall, R. Glasspool, 2014, British Journal of Cancer.

Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival.

H. Mackay, D. Cameron, R. Brown, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients

H. Gabra, P. Vasey, J. Smyth, 2007, Clinical Cancer Research.

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor

M. Gore, J. Ledermann, G. Rustin, 2019, Gynecologic oncology.

Carcinoembryonic antigen (CEA) testing in colorectal cancer follow up: what do patients think?

M. Mackean, N. Steele, G. Knowles, 2007, Postgraduate Medical Journal.

Improving outcomes for limited stage small cell lung cancer patients in Scotland with concomitant chemoradiation.

G. Kerr, A. Price, S. Erridge, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

How many cisplatin administration protocols does your department use?

D. Jodrell, M. Mackean, A. Greystoke, 2010, European journal of cancer care.

Improved Treatment and Survival for Lung Cancer Patients in South-East Scotland

A. Price, S. Erridge, M. Mackean, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer.

E. Frangou, R. Glasspool, S. Love, 2021, Gynecologic oncology.

Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.

R. L. Hollis, M. Churchman, C. Herrington, 2019, Gynecologic oncology.

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse 1

R. L. Hollis, C. Semple, M. Churchman, 2019 .

Higher Incidence of Isolated Brain Metastases in Ovarian Cancer Patients With Previous Early Breast Cancer

J. Smyth, D. Faratian, C. Gourley, 2010, International Journal of Gynecologic Cancer.

Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC).

M. Gore, J. Ledermann, G. Rustin, 2015 .

Understanding patient barriers and facilitators to uptake of lung screening using low dose computed tomography: a mixed methods scoping review of the current literature

A. Akram, K. Robb, A. Neilson, 2022, Respiratory research.

Optimizing the implementation of lung cancer screening in Scotland: Focus group participant perspectives in the LUNGSCOT study

A. Akram, R. Steele, K. Robb, 2022, Health expectations : an international journal of public participation in health care and health policy.

A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer

G. Strathdee, M. Mackean, R. Brown, 1999, Oncogene.

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations

R. L. Hollis, C. Semple, M. Churchman, 2018, BMC Cancer.

The National Lung Matrix Trial of personalized therapy in lung cancer

C. Swanton, N. O'Rourke, L. Billingham, 2020, Nature.

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real‐life experience

R. Glasspool, I. McNeish, M. Porteous, 2018, BJOG : an international journal of obstetrics and gynaecology.

Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification

R. L. Hollis, C. Semple, M. Churchman, 2021, npj Precision Oncology.

Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data

R. L. Hollis, M. Churchman, C. Herrington, 2020, BJOG : an international journal of obstetrics and gynaecology.

Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse

R. L. Hollis, C. Semple, M. Churchman, 2019, American journal of obstetrics and gynecology.

Interventions for the treatment of borderline ovarian tumours.

H. Dickinson, A. Bryant, C. Gourley, 2010, The Cochrane database of systematic reviews.

A cautionary lesson on the use of targeted methods for EGFR mutation analysis: a case report

R. Butler, A. Oniscu, D. Stirling, 2014, Journal of Clinical Pathology.

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

R. L. Hollis, A. Okamoto, C. Semple, 2020, Nature Communications.

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

J. Lubiński, J. Carmichael, J. Schellens, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.

G. Kerr, A. Price, S. Erridge, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

B. Reigner, J. Verweij, J. Schellens, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer

M. Stares, J. Leach, I. Phillips, 2021, Frontiers in Nutrition.

Histologic assessment of tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer.

S. Howie, Wei Wang, W. Wallace, 2013, Chest.

Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer

A. Dover, M. Strachan, T. Rye, 2018, Diabetic medicine : a journal of the British Diabetic Association.

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

T. Hickish, A. Norman, M. Nicolson, 1999, British Journal of Cancer.

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

D. Jodrell, J. Cassidy, M. Mackean, 1998, British Journal of Cancer.

Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma

R. L. Hollis, M. Churchman, J. Thomson, 2019, Gynecologic oncology.

Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre

M. Stares, I. Phillips, M. Mackean, 2023, Cancers.

Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer.

M. Gore, R. Glasspool, S. Halford, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complementary and Alternative Medicine Use Among Women Receiving Chemotherapy for Ovarian Cancer in 2 Patient Populations

H. Mackay, M. Mackean, S. Ferguson, 2011, International Journal of Gynecologic Cancer.

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer

M. Stares, K. Cumming, I. Phillips, 2022, ESMO open.

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

D. Jodrell, C. Twelves, J. Cassidy, 1998, British Journal of Cancer.

Defining the road map to a UK national lung cancer screening programme.

R. Booton, R. Rintoul, A. Akram, 2023, The Lancet. Oncology.

Modelling the Long-Term Effects of Covid-19 Cancer Services Disruption on Patient Outcome in Scotland

M. Dunlop, P. Hall, M. Mackean, 2021, medRxiv.

Use of complementary medicine (CAM) among women receiving chemotherapy for ovarian cancer: A comparison of attitudes between two patient populations.

H. Mackay, M. Mackean, S. Ferguson, 2009, Journal of Clinical Oncology.

Early prehabilitation in suspected locally advanced and metastatic lung cancer

N. Macdonald, I. Phillips, M. Mackean, 2023, BMJ supportive & palliative care.

Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC).

H. Gabra, P. Vasey, J. Smyth, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.

M. Fallon, S. Fleetwood-Walker, M. Mackean, 2010, Journal of pain and symptom management.

Edinburgh Research Explorer Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma

R. L. Hollis, A. Biankin, A. Matakidou, 2022 .

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study.

R. Knoblauch, R. Gentzler, M. Mackean, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

M. Stares, M. Mackean, C. Barrie, 2023, Cancers.